Viral Hepatitis

Joe Doyle

Project leader: Joseph Doyle

Phone: +61 3 9076 9043
Email: joseph.doyle@monash.edu

Doyle research group

Deputy Program Director, Disease Elimination;

Co-Head, Viral Hepatitis Research;

NHMRC Clinical Research Fellow

Eliminate Hepatitis

Hepatitis C affects 230,000 people in Australia. Currently, only one to two per cent of people with chronic HCV are treated annually.

In 2016, the World Health Organization (WHO) set targets to reduce new HCV infections by 80 per cent, reduce deaths due to HCV by 65 per cent, and eliminate HCV as a public health problem by 2030.

With new, effective non-interferon-based treatments, it should be possible for Australia to achieve these elimination targets.

Key to our success in reducing HCV-related deaths and new infections in Australia will be the upscaling of treatment for all people with chronic HCV infection, including those currently transmitting HCV who are chiefly people who inject drugs.

New community-based treatment programs in primary care, drug and alcohol services, and community organisations are being rolled out locally. We are exploring the supports needed for prescribers to start treatment and the expectations of people living with HCV from their medical services. The outcomes will help facilitate treatment uptake and improve the quality of care.

-

One life, one Liver: hepatitis can devastate both

Finalist, Eureka Prize for Emerging Leader in Science Professor Joseph Doyle is committed to achieving the World Health Organization goal of eliminating viral hepatitis, which affects more than 300 million people globally. Through partnerships spanning hospitals, universities, community and government, he has innovated and implemented new models of testing, care and treatment, to improve outcomes for the 300,000 Australians living with viral hepatitis.

Watch the video to learn more.